Filed in archive
Drugs, Vaccines and Therapeutics
, Genomics, Proteomics and Bioinformatics
by ruth on February 19, 2007

Oblimersen is an experimental agent that inhibits the production of a protein known as Bcl-2 in cancer cells. This protein can stop a cell from destroying itself, and is often over-expressed in cancer. As an antisense drug, oblimersen provides a complementary genetic strand to the messenger RNA that produces Bcl-2, inactivating it and preventing the protein from being produced. "It gets rid of Bcl-2, and cells that have less Bcl-2 are more sensitive to chemotherapy," O'Brien says.
According to the results, oblimersen produced a four-fold increase in CP/nPR, a clinical response defined by no definitive evidence of disease among patients who were sensitive to the chemotherapy drug fludarabine. In addition, survival was found to be three or more years in 70 percent of the patients in the oblimersen group compared with 38% in the chemotherapy-alone group. According to the researchers, oblimersen may represent a new treatment option for this subset of CLL patients whose disease has progressed, but who are still sensitive to chemotherapy.
Source: UT MD Anderson Cancer Center
Tags:
leukemia
antisense
gene+therapy
biotech
drug
antisense+drug
lymphocytic+leukemia
first+antisense
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/54283
Mr Wong
Vote for First Antisense Drug for Chemotherapy-Responsive Chronic Lymphocytic Leukemia:
|
Rating: 8.00 out of 3 vote(s) cast.
|
Response from:
Drug Addiction
(05/17/07 8:26am)
I really understood this mechanism but my question is : how are the doctors sure this will work as long as there are an incredible amount of factors that could influence the final result ?
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |







